Joint Press Release: Grünenthal and OnDosis team up for individualised dosing of oral drugs in pain management to increase patient safety

Aachen, Germany and Gothenburg, Sweden (ots) -

- Grünenthal expands its portfolio with an innovative technology for
individualised dosing
- Life science startup OnDosis signs its first global development and
licensing agreement for their innovative technology

Grünenthal and OnDosis announced today that they have entered into
an exclusive collaboration to develop the OnDosis' technology for
prescription medicines in all pain related indications. The agreement
also entails an option for Grünenthal to an exclusive worldwide
license to the technology in these indications. The handheld device
enables individualised dosing of oral medicines in micro units,
provides support for patient compliance, can be combined with digital
solutions and thus significantly improves patients' safety. The
agreement with Grünenthal, a leading pain specialist, is the first
partnering deal for life science startup OnDosis on their innovative
technology. While this agreement covers the indication area pain;
other focus areas of OnDosis, like ADHD and immunosuppression, remain
available for further cooperation with third parties.

"We are thrilled to enter our first partnering agreement with the
leading pain company Grünenthal to further explore how our technology
can generate added value for pain patients. This agreement is
obviously an import milestone and a clear evidence of the interest in
our technology," says Martin Olovsson, CEO of OnDosis.

"We constantly strive to develop innovative, convenient and safe
solutions for patients. Beyond individualised dosing, OnDosis can
serve as an interface to digital applications that may further
support a holistic approach to pain management in the future. It's a
perfect strategic fit and complements our portfolio of pain
medicines", says Gabriel Baertschi, CEO of Grünenthal.

As part of the agreed terms, OnDosis will receive a technology
access fee in addition to later development and regulatory milestone
payments, as well as sales related royalties. Financial terms of the
agreement were not disclosed.

About Grünenthal

Grünenthal is an entrepreneurial, science-based pharmaceutical
company specialized in pain, gout and inflammation. Our ambition is
to deliver four to five new products to patients in diseases with
high unmet medical need by 2022 and become a EUR 2 bn company. We are
a fully integrated research & development company with a long track
record of bringing innovative pain treatments and state-of-the-art
technologies to patients. By sustainably investing in our R&D above
the industrial average, we are strongly committed to innovation.
Grünenthal is an independent, family-owned company headquartered in
Aachen, Germany. We are present in approx. 30 countries with
affiliates in Europe, Latin America and the US. Our products are sold
in more than 100 countries and approx. 5,200 employees are working
for Grünenthal worldwide. In 2017, Grünenthal achieved revenues of
approx. EUR 1.3 bn.

More information: www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group
Twitter: @grunenthalgroup
Instagram: gruenenthal

About OnDosis

Swedish life science company OnDosis has developed a proprietary
technology to deliver flexible and individualised dosing of oral
medicines. By integrating medicines with intelligent dosing and
digital capabilities in a handheld device, OnDosis offers a new way
to take oral medicines - in micro units. Individualised, intuitive
and intelligent. Initial focus areas are pain, ADHD and
immunosuppression. OnDosis is a spin-out from AstraZeneca and
headquartered in Gothenburg, Sweden.

More information at www.ondosis.com

Follow us on: LinkedIn: OnDosis

For more information, please contact:

Stepán Krácala
Head Global Communications
Tel.: +49 241 569-1335
Stepan.Kracala@grunenthal.com
Grünenthal GmbH, 52099 Aachen, Germany

Kerstin Nacken, Head Editorial Management and Media Relations
Tel.: +49 241 569-2710,
Kerstin.Nacken@grunenthal.com
Grünenthal GmbH, 52099 Aachen, Germany

Martin Olovsson
Chief Executive Officer
Tel. +46 (0)76-772 8501
OnDosis AB, Pepparedsleden 1, 431 50 Mölndal, Sweden
martin.olovsson@ondosis.com

Original-Content von: Grünenthal Group, übermittelt durch news aktuell